Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vulnerability and Risk of Neuropathic Pain in Cancer: Validation of a Predictive Tool to Optimize Treatment.

NCT06511674 is registered in ClinicalTrials.gov with University Hospital, Clermont-Ferrand as lead sponsor.

NCT NCT06511674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06511674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vulnerability and Risk of Neuropathic Pain in Cancer: Validation of a Predictive Tool to Optimize Treatment.
Lead sponsor
University Hospital, Clermont-Ferrand
Phase
Not applicable
Overall status
Recruiting
Start date
October 28, 2024
Completion date
June 30, 2028
Enrollment
625 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, neuropathic pain, predictive